Novartis CAR-T trial disclosures have put fresh scrutiny on autoimmune risk after three deaths were reported in the company’s studies. The incidents are reigniting questions about what level of immune-mediated toxicity remains acceptable for CAR-T approaches as the modality expands beyond oncology. The deaths highlight the potential trade-offs when CAR-T is used in conditions that involve immune dysregulation, where on-target and off-target effects can be difficult to anticipate and manage. For sponsors pursuing autoimmune indications, the disclosures may drive tighter patient monitoring, more conservative manufacturing and enrollment approaches, and revised risk-management frameworks across future studies.